BACKGROUND: Multi-class HIV-1 resistant variants are not rare nowadays. Genotypic and phenotypic resistance testing (including virtual phenotype) constitutes an important tool for optimizing antiretroviral treatment. AIM: To report a case of discrepancy between resistance interpretation and virological outcome. METHODS: A case of a multi-drug experienced patient is presented. Genotypic and/or virtual phenotypic testing analysis was used. RESULTS: The patient after 10 years of antiretroviral therapy with 11 different regimens unable to produce full virological suppression and with a rapidly declining CD4 count, achieved a successful virological outcome with a scheme containing Tipranavir boosted with low dose of ritonavir. Of note, the patient was screened for Tipranavir 1182.48 study and was found ineligible after genotypic analysis. CONCLUSIONS: Virologic suppression was achieved despite the fact that neither an active agent was included in the backbone regimen nor the resistance profile could ensure the effectiveness of Tipranavir.
BACKGROUND: Multi-class HIV-1 resistant variants are not rare nowadays. Genotypic and phenotypic resistance testing (including virtual phenotype) constitutes an important tool for optimizing antiretroviral treatment. AIM: To report a case of discrepancy between resistance interpretation and virological outcome. METHODS: A case of a multi-drug experienced patient is presented. Genotypic and/or virtual phenotypic testing analysis was used. RESULTS: The patient after 10 years of antiretroviral therapy with 11 different regimens unable to produce full virological suppression and with a rapidly declining CD4 count, achieved a successful virological outcome with a scheme containing Tipranavir boosted with low dose of ritonavir. Of note, the patient was screened for Tipranavir 1182.48 study and was found ineligible after genotypic analysis. CONCLUSIONS: Virologic suppression was achieved despite the fact that neither an active agent was included in the backbone regimen nor the resistance profile could ensure the effectiveness of Tipranavir.
Authors: John D Baxter; Thomas C Merigan; Deborah N Wentworth; James D Neaton; Marie L Hoover; Richard M W Hoetelmans; Stephen C Piscitelli; Werner H A Verbiest; Douglas L Mayers Journal: AIDS Date: 2002-05-24 Impact factor: 4.177
Authors: Cristina Tural; Lidia Ruiz; Christopher Holtzer; Jonathan Schapiro; Pompeyo Viciana; Juan González; Pere Domingo; Charles Boucher; C Rey-Joly; Bonaventura Clotet Journal: AIDS Date: 2002-01-25 Impact factor: 4.177
Authors: Carlo Torti; Eugenia Quiros-Roldan; Mario Regazzi; Andrea De Luca; Francesco Mazzotta; Andrea Antinori; Nicoletta Ladisa; Valeria Micheli; Anna Orani; Andrea Patroni; Paola Villani; Sergio Lo Caputo; Francesca Moretti; Simona Di Giambenedetto; Filippo Castelnuovo; Paolo Maggi; Carmine Tinelli; Giampiero Carosi Journal: Clin Infect Dis Date: 2005-05-12 Impact factor: 9.079